This presentation was developed in English.

 

The onset of neurodegenerative disorders has increased exponentially with age, suggesting that the brain is particularly susceptible to the aging process. Alzheimer's disease starts with an asymptomatic stage and biomarker evidence of the condition and progresses by expressing mild cognitive and/or neurobehavioral abnormalities until it reaches the state of dementia.
The hippocampus, essential in the regulation of learning and memory, is the brain structure most affected by Alzheimer's disease. It exhibits incredible structural and functional plasticity in response to environmental changes, making it an important target for research.
Aducanumab, a kind of human monoclonal antibody, has been approved by the U.S. Food and Drug Administration to treat Alzheimer's patients. It will be available in the US from June 7, 2021.
Aducanumab has emerged as the most promising treatment for AD during the past ten years. Other non-pharmacological therapies, stem cell therapy and hyperbaric oxygen therapy are two potential candidates to help prevent and/or treat Alzheimer's.
Early diagnosis of AD allows access to treatment options that do not cure the disease but reduce cognitive and functional decline at an early stage. It also opens new horizons for people to change their lifestyle to prevent aging related diseases and stay healthy longer.